Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 ...
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform Alto Neuroscience's ALTO-100 Phase 2b study for major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback